Unraveling the genomic determinants of response to CDK4/6 inhibitors

por Litchfield, Lacey M., Webster, Vue W., Buchanan, Sean G.
Publicado 2018

Reduced Expression of miR-200 Family Members Contributes to Antiestrogen Resistance in LY2 Human Breast Cancer Cells

por Manavalan, Tissa T., Teng, Yun, Litchfield, Lacey M., Muluhngwi, Penn, Al-Rayyan, Numan, Klinge, Carolyn M.
Publicado 2013

β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression

por JAFAAR, ZAINAB M.T., LITCHFIELD, LACEY M., IVANOVA, MARGARITA M., RADDE, BRANDIE N., AL-RAYYAN, NUMAN, KLINGE, CAROLYN M.
Publicado 2014

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

por Wander, Seth A, O’Brien, Neil, Litchfield, Lacey M, O’Dea, Declan, Morato Guimaraes, Claudia, Slamon, Dennis J, Goel, Shom
Publicado 2022

Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer

por Litchfield, Lacey M., Mukherjee, Abir, Eckert, Mark A., Johnson, Alyssa, Mills, Kathryn A., Pan, Shawn, Shridhar, Viji, Lengyel, Ernst, Romero, Iris L.
Publicado 2015

Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on...

por Rao, Xi, Chen, Yongmei, Beyrer, Julie, Nash Smyth, Emily, Morato Guimaraes, Claudia, Litchfield, Lacey M., Bowman, Lee, Lawrence, Garreth W., Aggarwal, Amit, Andre, Fabrice
Publicado 2023

Identification and Characterization of Nucleolin as a COUP-TFII Coactivator of Retinoic Acid Receptor β Transcription in Breast Cancer Cells

por Litchfield, Lacey M., Riggs, Krista A., Hockenberry, Alyson M., Oliver, Laura D., Barnhart, Katelyn G., Cai, Jian, Pierce, William M., Ivanova, Margarita M., Bates, Paula J., Appana, Savitri N., Datta, Susmita, Kulesza, Piotr, McBryan, Jean, Young, Leonie S., Klinge, Carolyn M.
Publicado 2012

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells

por Litchfield, Lacey M., Boehnke, Karsten, Brahmachary, Manisha, Mur, Cecilia, Bi, Chen, Stephens, Jennifer R., Sauder, J. Michael, Gutiérrez, Sonia M., McNulty, Ann M., Ye, Xiang S., Wu, Wenjuan, Lallena, María José, Gong, Xueqian, Merzoug, Farhana F., Jansen, Valerie M., Buchanan, Sean G.
Publicado 2020

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

por Tolaney, Sara M., Beeram, Muralidhar, Beck, J. Thaddeus, Conlin, Alison, Dees, E. Claire, Puhalla, Shannon L., Rexer, Brent N., Burris, Howard A., Jhaveri, Komal, Helsten, Teresa, Becerra, Carlos, Kalinsky, Kevin, Moore, Kathleen N., Manuel, Allison M., Lithio, Andrew, Price, Gregory L., Chapman, Sonya C., Litchfield, Lacey M., Goetz, Matthew P.
Publicado 2022